Prime Medicine, Inc.
Prime Medicine, Inc. (PRME) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PRME · as of Jun 8, 2026
Key Statistics
Explore Prime Medicine, Inc. Data
prme stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 55.6%
The PRME analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $17.25, representing +463.73% upside from the current price of $3.06.
Competitors & Peers
prme competitorsPRME
BCAX
EYPT
KURA
MRVI
PROKStock Performance
Full HistoryAbout Prime Medicine, Inc.
Prime Medicine, Inc. a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fu…
what is prime medicine, inc. · prme stock overview · prime medicine, inc. company profile · who is prime medicine, inc. ceo · prme NASDAQ · prime medicine, inc. headquarters · prime medicine, inc. business segments
About Stock Overview & Key Data
Prime Medicine, Inc. (PRME) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 20, 2022. As of the latest trading session, PRME stock price is $3.06, with a market capitalization of $552.7M. The stock has returned +83.23% over the past 12 months and -11.82% year-to-date.
According to 9 Wall Street analysts, the consensus rating for Prime Medicine, Inc. stock is Buy, with an average 12-month price target of $17.25. In fiscal year 2025, Prime Medicine, Inc. reported revenue of $4.6M and net income of -$201.1M. For detailed data — including Prime Medicine, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Prime Medicine, Inc. (PRME) stock price is $3.06. The stock is traded on NASDAQ under the ticker symbol PRME. The 52-week range is $1.30 – $6.94.